Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance Database

Drugs - Real World Outcomes

Volumn 3, Issue 1, 2016, Pages 107-114

  Wang, Bruce C M ^a   Hsu, Ping Ning ^b   Furnback, Wesley ^a   Ney, John ^c   Yang, Ya Wen ^d   Fang, Chi Hui ^d   Tang, Chao Hsiun ^e  

^a Elysia Group LLC   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Pfizer Limited   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CELECOXIB; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; ETODOLAC; ETORICOXIB; HYDROXYCHLOROQUINE; MELOXICAM; METHOTREXATE; NABUMETONE; NIMESULIDE; PENICILLAMINE; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE;

ABSENTEEISM; ADOLESCENT; ADULT; AGED; ANGIOPLASTY CATHETER; ARTICLE; CHILD; CONTROLLED STUDY; COST OF ILLNESS; DATA BASE; DISEASE SEVERITY; DRAINAGE TUBE; DRUG COST; EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY; FEMALE; FULL TIME EMPLOYMENT; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NATIONAL HEALTH INSURANCE; ORTHOPEDIC EQUIPMENT; PRESCRIPTION; PRESENTEEISM; PRIORITY JOURNAL; PRODUCTIVITY; RHEUMATOID ARTHRITIS; URBAN POPULATION; URETER CATHETER; UROLITHIASIS; WORKING TIME;

EID: 84991016659     PISSN: 21991154     EISSN: 21989788     Source Type: Journal    
DOI: 10.1007/s40801-016-0063-8     Document Type: Article

References (32)

1. Khan MA. Update on Spondyloarthropathies. Ann Intern Med. 2002;136:896–907.
2. Uhlig T, Moe RH, Kvien TK. The burden of disease in rheumatoid arthritis. Pharmacoeconomics. 2014;32(9):841–51.
3. Barnabe C, Thanh NX, Ohinmaa A, et al. Effect of remission definition on healthcare cost savings estimates for patients with rheumatoid arthritis treated with biologic therapies. J Rheumatol. 2014;41:1600–6.
4. Filipovic I, Walker D, Forster F, Curry AS. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1083–90.
5. Kalkan A, Hallert E, Bernfort L, Husberg M, Carlsson P. Costs of rheumatoid arthritis during the period 1990–2010: a register-based cost-of-illness study in Sweden. Rheumatology (Oxford). 2014;53:153–60.
6. Turchetti G, Bellelli S, Mosca M. The social cost of rheumatoid arthritis in Italy: the results of an estimation exercise. Reumatismo. 2013;65:271–7.
7. Birnbaum H, Pike C, Kaufman R, et al. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010;26:77–90.
8. Cross M, Smith E, Hoy D, Carmona L. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Annal rheumatic diseases 2014;73:1316–22.
9. Hsiao F-Y, Yang C-L, Huang Y-T, Huang W-F. Using Taiwan’s National Health Insurance research database for pharmacoepidemiology research. J Food Drug Anal. 2007;15:99–108.
10. Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Yu KH. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. Rheumatol Int. 2013;33:355–60.
11. National Health Insurance Research Database, Taiwan. Available at: http://nhird.nhri.org.tw/en/index.htm. Accessed 26 Oct 2015.
12. Chen GL, Hsiao FY, Dong YH, Shen LJ, Wu FL. Statins and the risk of liver injury: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2014;23(7):719–25.
13. Chiang FY, Lu IC, Kuo WR, Lee KW, Chang NC, Wu CW. The mechanism of recurrent laryngeal nerve injury during thyroid surgery–the application of intraoperative neuromonitoring. Surgery. 2008:743–9.
14. Huang WY, Wu SC, Chen YF, Lan CF, Hsieh JT, Huang KH. Surgeon volume for percutaneous nephrolithotomy is associated with medical costs and length of hospital stay: a nationwide population-based study in Taiwan. J Endourol. 2014;28(8):915–21. doi:10.1089/end.2014.0003.
15. Wang JY, Wang CY, Huang YS, et al. Increased risk of ischemic stroke after hyperosmolar hyperglycemic state: a population-based follow-up study. PLoS One. 2014;9:e94155.
16. Classification of Diseases, Functioning, and Disability, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Center for Disease Control and Prevention, 2011. http://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed 18 July 2011.
17. Reilly MC, Zbrozek AS, Dukes E. The validity and reproducibility of a work productivity and activity impairment measure. PharmacoEconomics. 1993;4(5):353–65.
18. Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rhuematology. 2010;49(4):812–9. doi:10.1093/rheumatology/kep457.
19. Chaparro del Moral R, Rillo OL, Casalla L, et al. Work productivity in rheumatoid arthritis: relationship with clinical and radiological features. Arthritis. 2012;2012:7. doi:10.1155/2012/137635 (Article ID 137635).
20. Google Finance. US Dollar ($)—New Taiwan Dollar (NT$). https://www.google.com/finance?q=USDTWD. Accessed 16 Dec 2014.
21. Tang CH, Hsu PN, Tsai ST, Shen CY, Tsai WC, et al. Health-state utilities in measuring health-related quality of life among patients with rheumatoid arthritis in Taiwan. A Poster presented at ISPOR European Congress held in Dublin, Ireland, 2–6 November 2013.
22. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies: III. Design options. Am J Epidemiol. 1992;135:1042–50.
23. Wang B, Tang CH, Furnback W, Ney J, Yang YW, Fang CH, Huang YH. Disease burden of ankylosing spondylitis in Taiwan: a population-based analysis. In: European league against rheumatism meeting, Rome, 2015.
24. Wang B, Tang CH, Furnback W, Ney J, Yang YA, Fang CH, Huang YH. Disease burden of psoriatic arthritis in Taiwan: a population-based analysis. In: International society for pharmacoeconomics and outcomes research international meeting, Philadelphia, 2015.
25. Hsu JY, Chuang PY, Lin YS, Hsu PN, Tang CH. Using health assessment questionnaire—disability index to estimate EQ-5D utility values for patients with rheumatoid arthritis in Taiwan. A poster presented at ISPOR European Congress held in Amsterdam, Netherland, 8–12 November 2014.
26. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
27. Kleinman NL, Cifaldi MA, Smeeding JE, Shaw JW, Brook RA. Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis. J Occup Environ Med. 2013;55:240–4.
28. Chung SD, Hung SH, Lin HC, Lin CC. Health care service utilization among patients with chronic rhinosinusitis: a population-based study. Laryngoscope. 2014;124:1285–9.
29. Chen K-C, Hung S-T, Yang C-WW, Tsai T-F, Tang C-H. The economic burden of psoriatic diseases in Taiwan. J Dermatol Sci. 2014;75:183–9.
30. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010;26(1):77–90.
31. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008;58:15–25.
32. National Statistics. Republic of China (Taiwan). Earnings and Productivity Statistics in August 2015. October 22, 2015. Available at: http://eng.stat.gov.tw/public/Data/5102284719W7OZ7PW0.pdf. Accessed 26 Oct 2015.